Last reviewed · How we verify

Primary adrenocortical insufficiency — Treatment Landscape & Competitive Intelligence

Primary adrenocortical insufficiency (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Primary adrenocortical insufficiency, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Decadron dexamethasone Generic (originally Merck) Corticosteroid [EPC] Annexin A1, Interleukin-4, Androgen receptor 1958-10-30
Medrol methylprednisolone Generic (originally Upjohn/Pfizer) Glucocorticoid (corticosteroid) Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor 1957-10-01
Deltasone prednisone Generic (originally Schering) Corticosteroid [EPC] Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor 1955-01-01
Prelone prednisolone Generic (originally Schering) Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Solu-Cortef hydrocortisone succinate Pfizer Corticosteroid Glucocorticoid receptor 1955-01-01
Florinef fludrocortisone Generic Mineralocorticoid Annexin A1, Glucocorticoid receptor, Mineralocorticoid receptor 1954-01-01
Cortef hydrocortisone Generic (originally Merck/Upjohn) Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01
Cortisol Cortisol University of Zurich Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible
prednison prednison Wen Zhang Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor
prednisolon prednisolon Hannover Medical School Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 4 drugs in Primary adrenocortical insufficiency
  2. Generic (originally Schering) · 2 drugs in Primary adrenocortical insufficiency
  3. Generic (originally Merck) · 1 drug in Primary adrenocortical insufficiency
  4. Generic (originally Merck/Upjohn) · 1 drug in Primary adrenocortical insufficiency
  5. Generic (originally Upjohn/Pfizer) · 1 drug in Primary adrenocortical insufficiency
  6. Hannover Medical School · 1 drug in Primary adrenocortical insufficiency
  7. Leiden University Medical Center · 1 drug in Primary adrenocortical insufficiency
  8. Pfizer · 1 drug in Primary adrenocortical insufficiency
  9. University of Zurich · 1 drug in Primary adrenocortical insufficiency
  10. Wen Zhang · 1 drug in Primary adrenocortical insufficiency
  11. Generic · 1 drug in Primary adrenocortical insufficiency

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Primary adrenocortical insufficiency:

Cite this brief

Drug Landscape (2026). Primary adrenocortical insufficiency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/primary-adrenocortical-insufficiency. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing